肌成纤维细胞
纤维化
炎症
增稠
结肠炎
下调和上调
并发症
炎症性肠病
免疫学
转化生长因子β
胃肠病学
内科学
转化生长因子
肺纤维化
促炎细胞因子
细胞生物学
特发性肺纤维化
癌症研究
化学
医学
病理
生物
基因
生物化学
高分子科学
疾病
作者
Vivek Krishna Pulakazhi Venu,Laurie Alston,Mircea Iftinca,Yi-Cheng Tsai,Matthew Stephens,Vineetha Warriyar,Sonia Rehal,Grace Hudson,H Szczepanski,Pierre‐Yves von der Weid,Christophe Altier,Simon A. Hirota
出处
期刊:American Journal of Physiology-gastrointestinal and Liver Physiology
[American Physiological Society]
日期:2021-09-01
卷期号:321 (3): G280-G297
被引量:19
标识
DOI:10.1152/ajpgi.00338.2019
摘要
Fibrosis and increased muscle thickening contribute to stricture formation and intestinal obstruction, a complication that occurs in 30%–50% of patients with CD within 10 yr of disease onset. More than 50% of those who undergo surgery to remove the obstructed bowel will experience stricture recurrence. To date, there are no drug-based approaches approved to treat intestinal strictures. In the current submission, we identify NR4A1 as a novel target to treat inflammation-associated intestinal fibrosis.
科研通智能强力驱动
Strongly Powered by AbleSci AI